Search Results
118 items found for "ovarian cancer"
- Ep 52 with Dr. Benjamin Myers
University of Utah School of Medicine in Salt Lake City, UT, and an investigator with the Huntsman Cancer focuses on Smoothened and other class F GPCRs which play essential roles in embryonic development and in cancer Ben studied developmental and cancer signaling as a postdoctoral fellow with Philip Beachy at Stanford
- Gi/o GPCRs drive the formation of actin-rich tunneling nanotubes in cancer cells via a Gβγ/PKCα/FARP1/Cdc42 axis
GPCRs in Oncology and Immunology Gi/o GPCRs drive the formation of actin-rich tunneling nanotubes in cancer Using a model of human adrenocortical cancer cells, here we established that activation of the GPCR OXER1
- In Silico Design of Novel RGS2-Galpha-q Interaction Inhibitors with Anticancer Activity
signaling 2 (RGS2), a member of the R4 family of RGS proteins, is overexpressed in many solid breast cancers , and its levels in prostate cancer significantly correlate with the metastatic stage and poor prognosis All 10 compounds inhibited the growth of several RGS2 expressing cancers in cell culture assays. In addition, AJ-3 inhibited the migration of LNCaP prostate cancer cells in wound healing assays.
- LP2, a cyclic angiotensin-(1-7) analog extended with an N-terminal D-lysine, impairs growth of patient-derived xenografts of colorectal carcinoma in mice
rationales, we studied the capacity of LP2 to inhibit the growth of patient-derived xenografts of colorectal cancer on an untreated tissue array demonstrated that the AT 2 R expression is reduced in human colorectal cancer specificity, safety and stability, warrant further evaluation of LP2's inhibitory potential of colorectal cancer . " Authors P Namsolleck , L de Vries , G N Moll Tags AT(2)R , Agonist , Angiotensin , Cancer , GPCR
- Session VIII | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Institute for Diabetes and Cancer, Helmholtz Centre Munich, Germany, 2. " About Anastasia Georgiadi "Head of Junior Group Endocrine Pharmacology, Institute of Diabetes and Cancer Professional Background Since 2021 Group Leader, Institute for Diabetes and Cancer, Helmholtz Diabetes Centre, Munich 2018 - 2021 Project Team Leader, Institute for Diabetes and Cancer, Helmholtz Diabetes Munich 2015 - 2018 Postdoctoral fellow, Department of Adipose Tissue Biology, Institute for Diabetes and Cancer
- Targeting adenosine signaling for immuno-oncology
Potent inhibitors of ADO signaling are currently being tested in cancer patients, including in randomized immunologist, Dr Stagg is recognized for having identified the adenosine-producing enzyme CD73 as a new cancer John Stagg on the web University of Montréal Québec Cancer Consortium The University of Montreal Hospital
- RGS20 promotes non-small cell lung carcinoma proliferation via autophagy activation and inhibition of the PKA-Hippo signaling pathway
Background: Novel therapeutic targets are urgently needed for treating drug-resistant non-small cell lung cancer Regulator of G protein signaling 20 (RGS20) is identified as an upregulated factor in many cancers, yet Methods: Immunohistochemistry and lung cancer tissue microarray were used to verify the expression of role of RGS20 as a promising novel molecular marker and a target for future targeted therapies in lung cancer
- SSTR2 positively associates with EGFR and predicts poor prognosis in nasopharyngeal carcinoma
the receptor tyrosine kinases family and overexpression of EGFR has been linked to poor prognosis and cancer SSTR2 and EGFR was evaluated by immunohistochemistry (IHC) in 491 cases of NPC and 50 cases of non-cancerous High expression of SSTR2 and EGFR was significantly increased in NPC patients compared with non-cancerous
- Itaconate in host inflammation and defense
and conjecture a rationale for developing ITA-based therapeutics to treat inflammatory diseases and cancer Authors Dan Ye , Pu Wang , Lei-Lei Chen , Kun-Liang Guan , Yue Xiong Tags IRG1/ACOD1 , cancer , inflammatory
- Posters | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
PDF Program HERE < Back to Full Agenda Posters Interrogating The Role Of CELSR1 (ADGRC1) In Breast Cancer Caroline Formstone Abstract "Breast cancer is the most common form of cancer amongst women. Recent studies identify CELSR1, a key PCP gene, as a novel biomarker for early-stage breast cancer. The impact of CELSR1 on cancer progression, however, is unclear. Notably, our pilot data from luminal-type breast cancer cell lines representative of breast carcinomas
- GPR4 in the pH-dependent migration of melanoma cells in the tumor microenvironment
2022 Abstract Due to its high metastatic potential, malignant melanoma is one of the deadliest skin cancers In melanoma as well as in other cancers, acidification of the tumor microenvironment (= TME, inverse
- GPR56 signaling pathway network and its dynamics in the mesenchymal transition of glioblastoma
multifunctional adhesion GPCR involved in diverse biological processes ranging from development to cancer Despite its important role in cancer, its mechanism of action or signaling is not completely understood
- Ep 54 with Dr. JoAnn Trejo
control cell signaling by protease-activated receptors (PARs) and the impact on vascular inflammation and cancer research has focused on PAR1, which has important functions in hemostasis, thrombosis, inflammation, and cancer
- From outside to inside and back again: the lysophosphatidic acid-CCN axis in signal transduction
protein-coupled receptors (GPCRs), enhancing proliferation, adhesion, and migration in many types of cancer Our group previously reported that LPA induces production of CCN1 protein in human prostate cancer cell
- Session II | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Avila Zozaya "My doctoral research was focused on investigating the cellular effects of missense lung cancer-mutations Sciences, University of Alabama at Birmingham (UAB), Birmingham, Alabama, USA 5 O'Neal Comprehensive Cancer Van Meir pursued postdoctoral work at the Ludwig Institute for Cancer Research in San Diego and joined Van Meir has developed novel therapeutic approaches for cancer using oncolytic adenoviruses and anti-angiogenic translate these novel agents to testing in clinical trials with the hope to develop novel medicines for cancer
- Dr. GPCR Community Presentation | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Avila Zozaya "My doctoral research was focused on investigating the cellular effects of missense lung cancer-mutations
- CaaX-motif-adjacent residues influence G protein gamma (Gγ) prenylation under suboptimal conditions
Dysregulation of prenylation contributes to multiple disorders, including cancers and vascular and neurodegenerative repurposing statins as Ras oncogene inhibitors and the failure of using prenyltransferase inhibitors in cancer
- Comparative Analysis of the GNAI Family Genes in Glioblastoma through Transcriptomics and Single-Cell Technologies
Published date October 23, 2023 Abstract Glioblastoma multiforme (GBM) is one of the most aggressive cancers We used The Cancer Genome Atlas (TCGA) GBM genomic dataset to identify differentially expressed genes
- Ep 135 with Dr. Katarzyna Marcinkiewicz
Weill Cornell Graduate School of Medical Sciences in New York City, studying epigenetic changes in cancer
- Expression pattern and clinical significance of beta 2-adrenergic receptor in oral squamous cell carcinoma: an emerging prognostic indicator and future therapeutic target
However, the role of β2-AR in oral cancer is not well identified. Kumar Mohanty, Rajender Singh, Vijay Kumar, Uma Shankar Singh, Rakesh Kumar Singh Tags GPCR; OSCC; Oral cancer
- Session III | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Sabbagh undertook post-doctoral fellowships at the Ontario Cancer Institute and the University of Toronto projects aimed on drug discovery of small molecules for the treatment of inflammatory disorders and cancer Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer (IRIC the development of innovative treatments for a range of diseases, including psychiatric disorders and cancer
- Ep 58 with Dr. Juan José Fung
Scientist at GPCR Therapeutics, Inc , a drug discovery company focused on targeting GPCR heteromers in cancer
- Exploration of prognostic and treatment markers in hepatocellular carcinoma via GPCR-related genes analysis
Patients' data on HCC were sourced from the Liver Hepatocellular Carcinoma-Japan (LIRI-JP) and The Cancer dysfunction and exclusion (TIDE) algorithm was utilized to evaluate immune infiltration levels and genetic variations immunotherapy and common antitumor drugs was predicted via the database Genomics of Drug Sensitivity in Cancer
- Session IX / Technology capsule: Light on aGPCR signaling and function | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
His research experience includes phylogenetics and cancer epigenetics.
- Ep 75 with Vaithish Velazhahan
His undergraduate thesis work on studying the biochemical mechanisms of flavonoids in cancer using nuclear
- Ep 157 with Dr. Nagarajan Vaidehi
She is also the Associate Director of the City of Hope Comprehensive Cancer Center. Dr.
- GPR68-ATF4 signaling is a novel prosurvival pathway in glioblastoma activated by acidic extracellular microenvironment
Lorazepam, which has off target agonism of GPR68, is linked to worse clinical outcomes for a variety of cancers However, the role of tumor microenvironment acidification in GPR68 activation has not been assessed in cancer
- Ep 136 with Murat Tunaboylu & Ben Holland
After switching to biotech, Murat has built cell imaging software and lab robots to accelerate cancer